Status:
COMPLETED
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Lead Sponsor:
Centre Francois Baclesse
Conditions:
Endometrial Cancer
Chemotherapy Effect
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Through this study, The investigator believe to evaluate the impact in terms of overall quality of life of adjuvant chemotherapy in patients with locally advanced endometrial cancer at a distance from...
Detailed Description
Endometrial cancer is the fourth most common cancer in women in developed countries. The diagnosis is often made at a localized stage (67% of cases), making it a relatively good cancer prognosis with ...
Eligibility Criteria
Inclusion
- For all patients:
- Women over 18 years of age, with histologically confirmed histologic type 1 or type 2 endometrial adenocarcinoma, with FIGO postoperative II or III stage operated between 2011 and 2015, with at least 2 years of follow-up compared to the last course of chemotherapy;
- Recommended surgery such as hysterectomy and bilateral salpingo-oophorectomy, non-mandatory surgical nodal staging;
- Pelvic radiotherapy +/- lumbar-aortic irradiation, optional brachytherapy;
- No recurrence of endometrial cancer at baseline;
- Absence of evolutionary neurological antecedent (multiple sclerosis, neurodegenerative pathology ...);
- Absence of progressive psychiatric pathology (i.e. psychiatric hospitalization, bipolar disorder, schizophrenia, personality disorders ...);
- No opposition to the collection of data;
- Patient deemed fit to answer a written questionnaire.
- For the patient in the chemotherapy group - Chemotherapy after surgery that can be performed before or after radiotherapy
Exclusion
- For all patients:
- Sarcoma or carcinosarcoma;
- Stage FIGO I or IV;
- Macroscopic tumor residue after surgery;
- Recurrence of endometrial cancer or diagnosis of any other cancerous pathology after diagnosis of endometrial cancer (except non-melanotic skin tumors with complete excision), within 5 years;
- drug use;
- Abuse of alcohol.
- For the patient in the chemotherapy group
- Chemotherapy before surgery;
- Chemotherapy concomitant with radiotherapy
- For the patient in the group without chemotherapy
- \- Chemotherapy whether before or after surgery
Key Trial Info
Start Date :
March 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2020
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT03466788
Start Date
March 29 2018
End Date
March 28 2020
Last Update
December 18 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France, 14076
2
Centre Oscar Lambret
Lille, France
3
Centre Eugène Marquis
Rennes, France
4
Centre Henri Becquerel
Rouen, France